Optical Coherence Tomography - Guided Protocol for Left Main Percutaneous Coronary Intervention
NCT ID: NCT04248777
Last Updated: 2020-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
71 participants
INTERVENTIONAL
2018-05-18
2019-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does OCT Optimise Results of Stenting on the Left Main Stem
NCT04391413
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NCT04604197
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions
NCT06272643
Does Optical Coherence Tomography Optimise Results of Stenting
NCT01743274
OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease
NCT04878133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
left main PCI guided by OCT
The LM PCI strategy is guided by 3 OCT runs, according to a pre-defined standardized protocol.
standardised OCT-guided intervention
The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
standardised OCT-guided intervention
The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable or non-stable distal Left Main lesion (with or without previous Coronary Artery Bypass Graft), involving or not Left Anterior Descending and Coronary Circumflex ostias and requiring Percutaneous Coronary Intervention with a one or two stents strategy
* stable or non-stable ostial Left Anterior Descending and/or Coronary Circumflex lesion requiring Percutaneous Coronary Intervention with involvement of distal Left Main
* SYNTAX angiographic score \<23
* informed consent
Exclusion Criteria
* on-going acute STEMI
* on-going cardiogenic shock
* severe chronic renal failure (Cr Cl \<30 ml/min/m2)
* anticipated technical contra-indication to OCT (highly calcified lesions, severe proximal tortuosity)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Mutualiste Montsouris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas AMABILE, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Institut Mutualiste Montsouris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Besancon
Besançon, , France
Chu Bordeaux
Bordeaux, , France
Clinique Saint Augustin
Bordeaux, , France
Hôpital privé Saint Martin
Caen, , France
Chu Clermont Ferrand
Clermont-Ferrand, , France
Ch Chartres
Le Coudray, , France
Institut hospitalier Jacques Cartier
Massy, , France
Ch Annecy Genevois
Metz-Tessy, , France
CHU Nîmes
Nîmes, , France
Institut Mutualiste Montsouris
Paris, , France
Clinique Saint Hilaire
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARDIO-2017-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.